Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

摘要: We report the outcome of patients included in LNH-98.5 study, which compared cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) therapy 399 with diffuse large B-cell lymphoma (DLBCL) aged 60 80 years, a median follow-up time 10 years. Clinical event information was updated all living (with exception 3 patients) 2009. Survival end points were improved treated R-CHOP: 10-year progression-free survival 36.5%, 20% alone, overall 43.5% 27.6%. The same risk death due other diseases, secondary cancers, late relapses observed both study arms. Relapses occurring after 5 years represented 7% disease progressions. results from analysis confirm benefits tolerability addition CHOP. Our findings underscore need treat elderly as young patients, use curative chemotherapy.